Dear Ms. Rebar:

Please refer to your supplemental new drug application dated July 30, 2004, received July 30, 2005, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Arixtra® (fondaparinux sodium, injection).

We acknowledge receipt of your submissions dated January 28, March 31, May 17 and May 23, 2005.

This supplemental new drug application provides for the use of Arixtra (fondaparinux sodium, injection) in patients undergoing abdominal surgery who are at risk for thromboembolic complications.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert) and submitted labeling (package insert submitted May 23, 2005).

Please submit an electronic version of the FPL according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format - NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "FPL for approved supplement NDA 21-345/S-010." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are deferring submission of your pediatric studies for ages birth to 16 years until May 30, 2010.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments. The status of the postmarketing studies shall be reported annually according to 21 CFR 314.81. This commitment is listed below.
1. Deferred pediatric study under PREA for the treatment of prophylaxis of deep vein thrombosis which may lead to pulmonary embolism in patients undergoing abdominal surgery who are at risk for thromboembolic complications in pediatric patients ages birth to age 16.

Final Report Submission: May 30, 2010

Submit final study reports to this NDA. For administrative purposes, all submissions related to this pediatric postmarketing study commitment must be clearly designated “Required Pediatric Study Commitments”.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to the Division of Gastrointestinal and Coagulation Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Diane Moore, Regulatory Project Manager, at (301) 827-7476.

Sincerely,

{See appended electronic signature page}

Joyce Korvick, M.D., M.P.H.  
Acting Director  
Division of Gastrointestinal & Coagulation Drug Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

Enclosure
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Kathy Robie-Suh
5/26/05 01:06:45 PM
signing for Dr. Joyce Korvick